{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:58:39Z","timestamp":1787979519969,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jad.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:53:02Z","timestamp":1725292382000},"page":"583-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI\/SNRI? - Insights from the REAL-ESK study"],"prefix":"10.1016","volume":"367","author":[{"given":"Giacomo","family":"d\u2019Andrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Miuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Cavallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Marrangone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"De Filippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassillis","family":"Martiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Andriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Barlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Maria","family":"Dell'Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano L.","family":"Sensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.09.004_bb0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jad.2023.01.074","article-title":"Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability","volume":"328","author":"Adair","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.jad.2024.09.004_bb0010","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jad.2024.09.004_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2024.09.004_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12991-022-00392-4","article-title":"Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life","volume":"21","author":"Christensen","year":"2022","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.004_bb0025","series-title":"Esketamine in Treatment Resistant Depression: A Study Protocol for a Retrospective, Real-life, Multicentric Study","first-page":"212","author":"D\u2019Andrea","year":"2022"},{"issue":"4","key":"10.1016\/j.jad.2024.09.004_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13040697","article-title":"Investigating the role of maintenance TMS protocols for major depression: systematic review and future perspectives for personalized interventions","volume":"13","author":"d\u2019Andrea","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.jad.2024.09.004_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.euroneuro.2023.02.010","article-title":"Rethinking ketamine and esketamine action: are they antidepressants with mood-stabilizing properties?","volume":"70","author":"d\u2019Andrea","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"23","key":"10.1016\/j.jad.2024.09.004_bb0040","first-page":"00351","article-title":"Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): a post-hoc analysis from the REAL-ESK study group","volume":"S1064-7481","author":"d\u2019Andrea","year":"2023","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2024.09.004_bb0045","series-title":"Spravato, Summary of Product Characteristics","author":"EMA","year":"2019"},{"key":"10.1016\/j.jad.2024.09.004_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jad.2020.11.106","article-title":"Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI\/SNRI treatment","volume":"283","author":"Fagiolini","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 6","key":"10.1016\/j.jad.2024.09.004_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.8133su1c.02","article-title":"Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities","volume":"70","author":"Gaynes","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2024.09.004_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.09.004_bb2005","unstructured":"JASP Team (2022). JASP (Version 0.19.0)[MacOS 13.4]."},{"issue":"3","key":"10.1016\/j.jad.2024.09.004_bb0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/wps.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2024.09.004_bb0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2024.09.004_bb0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord."},{"issue":"5","key":"10.1016\/j.jad.2024.09.004_bb0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.09.004_bb0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1017\/S1092852913000540","article-title":"Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction","volume":"19","author":"Pehrson","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2024.09.004_bb0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/CEOR.S314111","article-title":"Healthcare resource consumption and related costs of patients estimated with treatment-resistant depression in Italy","volume":"13","author":"Perrone","year":"2021","journal-title":"ClinicoEcon. Outcomes Res."},{"key":"10.1016\/j.jad.2024.09.004_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115378","article-title":"Predicting outcome with intranasal Esketamine treatment: a machine-learning, three-month study in treatment-resistant depression (ESK-LEARNING)","volume":"327","author":"Pettorruso","year":"2023","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.jad.2024.09.004_bb0100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2024.09.004_bb0105","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/13651501.2022.2030757","article-title":"Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme","volume":"26","author":"Samalin","year":"2022","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.jad.2024.09.004_bb2000","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41380-021-01381-x","article-title":"A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","volume":"27","author":"Sforzini","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.09.004_bb0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1092852915000139","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors)","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724014769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724014769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T07:36:23Z","timestamp":1729150583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724014769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"alternative-id":["S0165032724014769"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.09.004","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI\/SNRI? - Insights from the REAL-ESK study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}